felbamate has been researched along with Nausea in 4 studies
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 7.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 6.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy." | 4.79 | Felbamate. ( Leppik, IE, 1995) |
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 3.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 2.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy." | 2.40 | Felbamate. ( Pellock, JM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harden, CL | 1 |
| Trifiletti, R | 1 |
| Kutt, H | 1 |
| Leppik, IE | 1 |
| Sachdeo, R | 1 |
| Narang-Sachdeo, SK | 1 |
| Shumaker, RC | 1 |
| Perhach, JL | 1 |
| Lyness, WH | 1 |
| Rosenberg, A | 1 |
| Pellock, JM | 1 |
2 reviews available for felbamate and Nausea
| Article | Year |
|---|---|
Felbamate.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interact | 1995 |
Felbamate.
Topics: Adult; Age Factors; Anemia, Aplastic; Anorexia; Anticonvulsants; Child; Drug Administration Schedule | 1999 |
1 trial available for felbamate and Nausea
| Article | Year |
|---|---|
Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Dr | 1997 |
1 other study available for felbamate and Nausea
| Article | Year |
|---|---|
Felbamate levels in patients with epilepsy.
Topics: Adolescent; Anorexia; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid | 1996 |